Early Prophylactic Aspirin for Aneurysmal Subarachnoid Hemorrhage (aSAH-ASA)
2026年6月7日 更新者:Ganzhou City People's Hospital
Study on the Efficacy and Safety of Early Prophylactic Use of Aspirin in Improving Prognosis of Patients With Aneurysmal Subarachnoid Hemorrhage: A Multicenter, Prospective, Double-Blind, Randomized Controlled Trial
This study is a multicenter, prospective, double-blind, randomized controlled trial designed to evaluate whether early prophylactic use of aspirin improves functional outcomes in patients with aneurysmal subarachnoid hemorrhage (aSAH).
Patients with aSAH who have undergone successful aneurysm securing will be randomly assigned to receive either aspirin plus standard care or a placebo plus standard care.
The study drug will be started within 48 hours of undergone successful aneurysm securing and continued for not less than 10 days and not more than 14 consecutive days.
The main goal is to compare the rate of favorable functional outcomes at 3 months between the two groups.
Secondary goals include evaluating the incidence of delayed cerebral ischemia, cerebral infarction, mortality, and safety outcomes such as major bleeding events.
調査の概要
詳細な説明
Aneurysmal subarachnoid hemorrhage (aSAH) is a life-threatening neurological emergency associated with high rates of morbidity and mortality.
Delayed cerebral ischemia (DCI) and subsequent cerebral infarction are major contributors to poor functional outcomes in survivors.
Antiplatelet agents such as aspirin have been hypothesized to reduce the risk of microthrombosis and DCI, but evidence for their early prophylactic use in aSAH remains limited and controversial.
This trial aims to investigate the efficacy and safety of early aspirin administration in improving long-term functional outcomes in aSAH patients.
Eligible patients will be randomized into two groups: the intervention group will receive 100 mg of oral aspirin daily for not less than 10 days and not more than 14 consecutive days, while the control group will receive an identical placebo.
All patients in both groups will receive standardized aSAH management according to current clinical guidelines, including nimodipine, blood pressure control, and supportive care.
The primary endpoint is the functional outcome measured by the modified Rankin Scale (mRS) at 3 months.
Secondary endpoints include incidence of clinical DCI at discharge, percentage of imaging DCI detected on CT/MRI at discharge, all-cause mortality at 3 months, and safety outcomes including major bleeding events.
研究の種類
介入
入学 (推定)
388
段階
- フェーズ 4
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究連絡先
- 名前:Weilong Huang, MD. PhD.
- 電話番号:+8618807971121
- メール:doctorhwl@163.com
研究連絡先のバックアップ
- 名前:Zhenyu zhang, MD. PhD.
- 電話番号:+8615297777969
- メール:623071778@qq.com
研究場所
-
-
Jiangxi
-
Ganzhou、Jiangxi、中国、341000
- Ganzhou People's Hospital
-
コンタクト:
- Qiuhuang Jiang, MD, PhD
- 電話番号:+8613607979100
- メール:jiangqh1968@126.com
-
コンタクト:
- Xinyun Ye, MD, PhD
- 電話番号:+8615979789987
- メール:yexinyun1270@163.com
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
いいえ
説明
Inclusion Criteria:
- Age ≥ 18 years and ≤ 80 years.
- Spontaneous subarachnoid hemorrhage (SAH) confirmed by non-contrast head CT.
- Diagnosis of ruptured intracranial aneurysm confirmed, and successfully treated by either surgical clipping or endovascular coiling within 48 hours of ictus.
- Hunt-Hess grade ≤ 4 or WFNS grade ≤ 4 (assessed within 48 hours of SAH onset).
- Fisher grade 2-4 or modified Fisher grade 1-4.
- No significant focal neurological deficit after aneurysm intervention, defined as NIHSS scores ≤ 1 in the following items: 5a (left arm motor), 5b (right arm motor), 6a (left leg motor), 6b (right leg motor), and 9 (language).
- Pre-morbid modified Rankin Scale (mRS) score ≤ 1 prior to SAH onset.
Exclusion Criteria:
- Hunt-Hess grade 5 or WFNS grade 5 (assessed within 48 hours of SAH onset).
- Patients requiring any intracranial stent or non-embolic intrasaccular device during aneurysm embolization, with post-procedural need for antiplatelet therapy.
- Angiogram-negative SAH.
- Note: Prior history of ruptured intracranial aneurysm or re-rupture of previously treated aneurysm is not excluded.
- Moderate-to-severe vasospasm demonstrated on pre-operative or intra-operative CTA/DSA in the emergency setting.
- SAH caused by non-saccular aneurysms, including mycotic, blood-blister, fusiform, or dissecting aneurysms, or cases without basal cistern subarachnoid hemorrhage.
- Significant pre-existing intracranial pathology at the time of enrollment, including but not limited to: traumatic brain injury, moyamoya disease, high suspicion or documented CNS vasculitis, severe fibromuscular dysplasia, arteriovenous malformation, arteriovenous fistula, significant cervical or intracranial atherosclerotic stenosis (≥70%), or malignant brain tumor.
- Medical conditions requiring chronic use of antiplatelet agents (aspirin, clopidogrel, or ticagrelor), such as transient ischemic attack, myocardial infarction, atrial fibrillation, prosthetic heart valve, arteriovenous fistula, unstable angina, or other conditions requiring thromboprophylaxis.
- Thrombocytopenia (platelet count <20,000/μL, excluding aggregation artifacts), active disseminated intravascular coagulation (DIC) at enrollment, or documented history of coagulopathy or bleeding diathesis.
- History of gastrointestinal bleeding or major systemic hemorrhage within 30 days, hemoglobin <8 g/dL at admission, INR ≥1.5, or severe hepatic impairment defined as AST, ALT, alkaline phosphatase (AP), or GGT >2 times the upper limit of normal.
- Creatinine clearance <30 mL/min.
- Severe comorbidities that may confound study outcomes, including but not limited to: multiple sclerosis, dementia, major depression, immunosuppressed state or during intensive immunosuppressive therapy, cancer with expected survival <1 year, multi-organ failure, or any other condition potentially causing cognitive impairment.
Contraindications to aspirin therapy, including:
- Hypersensitivity to aspirin, other salicylates, or any excipients in the formulation;
- History of asthma induced by salicylates or NSAIDs;
- Active peptic ulcer disease;
- Bleeding diathesis;
- Hepatic or renal failure;
- Uncontrolled severe heart failure;
- Concomitant use with methotrexate at doses ≥15 mg/week.
- Pregnancy or positive HCG test.
- Incomplete repair of the responsible aneurysm as judged by the treating physician, with high risk of early re-bleeding.
- History of head trauma within 3 months prior to SAH onset.
- Recent cerebral disease within 3 months prior to SAH onset, such as tumor, stroke, epilepsy, vasculitis, AVM, or hydrocephalus.
- History of psychiatric illness or seizure disorder.
- Breastfeeding women.
- Expected survival <1 year prior to SAH onset.
- Participation in another randomized clinical trial that may confound the evaluation of this study.
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Aspirin Group
Patients receive 100 mg aspirin once daily, initiated within 48 hours of undergone successful aneurysm securing and continued for not less than 10 consecutive days and not more than 14 consecutive days, plus standard care.
|
Aspirin 100 mg (1 tablet) administered orally, via nasogastric tube, or rectally within 48 hours after aneurysm embolization or surgical clipping, once daily, for a minimum of 10 consecutive days and a maximum of 14 consecutive days.
|
|
プラセボコンパレーター:Placebo Control Group
Patients receive identical-appearing placebo capsules once daily, initiated within 48 hours of undergone successful aneurysm securing and continued for not less than 10 consecutive days and not more than 14 consecutive days, plus standard care.
|
Placebo 1 tablet (identical in appearance to aspirin 100 mg) administered orally, via nasogastric tube, or rectally within 48 hours after aneurysm embolization or surgical clipping, once daily, for a minimum of 10 consecutive days and a maximum of 14 consecutive days.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Proportion of patients with mRS 0-2 at 90 days after randomization
時間枠:90 days after randomization
|
The proportion of patients with modified Rankin Scale (mRS) scores ranging from 0 to 2 at 90 days after randomization.
|
90 days after randomization
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Extended Glasgow Outcome Scale (eGOS) at 90 days
時間枠:90 days after randomization
|
Functional prognosis assessed by Extended Glasgow Outcome Scale (eGOS) at 90 days after randomization.
|
90 days after randomization
|
|
Ordinal shift analysis of mRS at 90 days (mRS 5 and 6 combined)
時間枠:90 days after randomization
|
Ordinal shift analysis of modified Rankin Scale scores at 90 days after randomization, with mRS grade 5 and 6 merged into one category.
|
90 days after randomization
|
|
Proportion of patients with mRS 0-3 at 90 days
時間枠:90 days after randomization
|
Proportion of patients with modified Rankin Scale scores of 0 to 3 at 90 days after randomization.
|
90 days after randomization
|
|
Mini-Mental State Examination (MMSE) score at 90 days
時間枠:90 days after randomization
|
Cognitive function assessed via Mini-Mental State Examination (MMSE) scale.
|
90 days after randomization
|
|
Extended Glasgow Outcome Scale (eGOS) at 1 year
時間枠:1 year after randomization.
|
Functional outcome assessed by Extended Glasgow Outcome Scale at 1 year after randomization.
|
1 year after randomization.
|
|
Ordinal shift analysis of mRS at 1 year (mRS 5 and 6 combined)
時間枠:1 year after randomization
|
Ordinal shift analysis of modified Rankin Scale scores at 1 year after randomization, combining mRS 5 and mRS 6 into a single category.
|
1 year after randomization
|
|
Proportion of mRS 0-2 at 1 year
時間枠:1 year after randomization.
|
Proportion of patients with modified Rankin Scale scores of 0 to 2 at 1 year after randomization.
|
1 year after randomization.
|
|
Proportion of patients with mRS 0-3 at 1 year
時間枠:1 year after randomization.
|
Percentage of subjects achieving modified Rankin Scale scores from 0 to 3 at one year after randomization.
|
1 year after randomization.
|
|
Mini-Mental State Examination (MMSE) score at 1 year
時間枠:1 year after randomization
|
Cognitive function evaluated by Mini-Mental State Examination (MMSE) scale.
|
1 year after randomization
|
|
Change in NIHSS score from baseline at discharge
時間枠:30 days/discharge, which ever is earlier
|
Changes in National Institutes of Health Stroke Scale (NIHSS) scores at discharge compared with baseline levels.
|
30 days/discharge, which ever is earlier
|
|
Incidence of clinical delayed cerebral ischemia at discharge
時間枠:30 days/discharge, which ever is earlier
|
Incidence rate of clinical delayed cerebral ischemia (DCI) observed at hospital discharge.
|
30 days/discharge, which ever is earlier
|
|
Percentage of radiological DCI on CT/MRI at discharge
時間枠:30 days/discharge, which ever is earlier
|
Proportion of patients with radiological delayed cerebral ischemia confirmed by cranial CT or MRI at hospital discharge.
|
30 days/discharge, which ever is earlier
|
|
Lesion volume of radiological DCI on CT/MRI at discharge
時間枠:30 days/discharge, which ever is earlier
|
Volume of lesions consistent with radiological delayed cerebral ischemia detected by cranial CT or MRI at hospital discharge.
|
30 days/discharge, which ever is earlier
|
|
Incidence of invasive interventions
時間枠:30 days/discharge, which ever is earlier
|
Incidence of invasive interventions including DSA and angioplasty performed during hospitalization.
|
30 days/discharge, which ever is earlier
|
|
Rate of cerebrospinal fluid shunt surgery within 3 months
時間枠:Within 3 months after randomization
|
Proportion of patients receiving cerebrospinal fluid shunt surgery within 3 months after randomization.
|
Within 3 months after randomization
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
All-cause mortality within 90 days after randomization
時間枠:90 days after randomization
|
Total all-cause mortality rate at 90 days after randomization.
|
90 days after randomization
|
|
In-hospital discharge mortality
時間枠:30 days/discharge, which ever is earlier
|
Mortality rate at the time of hospital discharge.
|
30 days/discharge, which ever is earlier
|
|
Incidence of symptomatic intracerebral hemorrhage
時間枠:30 days/discharge, which ever is earlier
|
Defined as neurological deterioration with NIHSS score increased by ≥4 points combined with intracranial hemorrhage confirmed by imaging examination.
|
30 days/discharge, which ever is earlier
|
|
Incidence of any new-onset intracranial hemorrhage
時間枠:30 days/discharge, which ever is earlier
|
Incidence of any new-onset intracranial hemorrhage
|
30 days/discharge, which ever is earlier
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
協力者
捜査官
- 主任研究者:QiuHua Jiang, MD. PhD.、Ganzhou People's Hospital, Ganzhou, Jiangxi Province, China
- 主任研究者:Zeguang Ren, MD. PhD.、Houston Methodist, Houston, USA
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (推定)
2026年6月1日
一次修了 (推定)
2029年5月1日
研究の完了 (推定)
2029年8月1日
試験登録日
最初に提出
2026年5月28日
QC基準を満たした最初の提出物
2026年6月7日
最初の投稿 (実際)
2026年6月11日
学習記録の更新
投稿された最後の更新 (実際)
2026年6月11日
QC基準を満たした最後の更新が送信されました
2026年6月7日
最終確認日
2026年6月1日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- GZPH-PJB2025-420-01
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
いいえ
IPD プランの説明
Individual participant data (IPD) cannot be shared due to patient privacy requirements, institutional policies, and legal and regulatory restrictions.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
いいえ
米国FDA規制機器製品の研究
いいえ
米国で製造され、米国から輸出された製品。
いいえ
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。